Evidence map›Paper›PMID 33357097›Full record

ArticleTechnology in cancer research & treatment

The

Zhen-Hua Du, Yu Xia, Qing Yang, Song Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zhen-Hua DuDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Yu XiaDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Qing YangDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.ORCID 0000-0002-3669-3537
Song GaoDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveWe have previously reported that

methodsThe

resultsIt was found that expression of BRCA2 protein in ovarian cancer cells transfected with

conclusionOver expression of mRNA and protein of BRCA2 was detected in the cells with

Indexed as

AllelesMutationBiomarkers, TumorBRCA2 ProteinCell Line, TumorCell SurvivalCisplatinDose-Response Relationship, DrugDrug Resistance, NeoplasmFemaleHumansOvarian NeoplasmsRad51 RecombinaseBiomarkers, TumorBRCA2 ProteinBRCA2 protein, humanCisplatinRAD51 protein, humanRad51 RecombinaseBRCA2 N372Hdrug resistanceovarian cancer

Identifiers

PMID33357097
PMCPMC7768310
OpenAlexW3116122913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.